Search

The article discusses research by Xueyan Bian from Ningbo University and, reported in the Clinical Nephrology issue, on August 19, 2024. Topics include the efficacy of sacubitril/valsartan versus valsartan alone in improving cardiac function and residual renal function in patients with diabetes and heart failure with preserved ejection fraction undergoing peritoneal dialysis, as well as the safety profile of the treatment.

The article reviews the association between sacubitril/valsartan treatment and the risk of Alzheimer's disease, focusing on long-term use of the drug. Topics discussed include the impact of sacubitril/valsartan on amyloid-beta accumulation, the current clinical evidence regarding cognitive decline, and the interpretation of blood-based amyloid biomarkers in this context.

A study conducted at the Third Affiliated Hospital in Guizhou, China, aimed to detect adverse reactions in the muscular system when sacubitril/valsartan (a combination drug used for cardiovascular conditions) is combined with statins (atorvastatin, rosuvastatin, simvastatin). The researchers analyzed a database of adverse reaction reports and found statistically significant correlation signals between the combination of sacubitril/valsartan and simvastatin with musculoskeletal muscle pain, as well as between sacubitril/valsartan and atorvastatin or simvastatin with myopathy. The study suggests that the coadministration of sacubitril/valsartan with these statins may increase the risk of myopathy and musculoskeletal pain, which should be closely monitored in clinical practice. [Extracted from the article]

A research study conducted at Yangtze University in Hubei, China, aimed to investigate the effect of sacubitril/valsartan on the early recurrence of atrial fibrillation after radiofrequency catheter ablation. The study involved 100 patients with paroxysmal atrial fibrillation and cardiac insufficiency, who were divided into experimental and control groups. The experimental group received sacubitril/valsartan after the ablation procedure, while the control group received perindopril tert-butylamine. The results showed that the experimental group had a significantly lower early recurrence rate compared to the control group. The researchers concluded that sacubitril/valsartan can effectively reduce the recurrence rate of atrial fibrillation after ablation and improve heart structure and function. [Extracted from the article]

A recent study conducted at Taipei Medical University Hospital in Taiwan examined the long-term outcomes of using sacubitril/valsartan (Entresto) in heart failure patients with reduced ejection fraction (HFrEF) and coexisting end-stage renal disease (ESRD). The study found that patients treated with sacubitril/valsartan had significantly lower 5-year all-cause mortality rates compared to those treated with candesartan or valsartan. Additionally, the sacubitril/valsartan group showed greater improvement in left ventricular ejection fraction (LVEF) after 3 years. The researchers concluded that sacubitril/valsartan is a beneficial treatment option for this patient population. [Extracted from the article]

A study conducted at the University of Mississippi examined the effects of sacubitril/valsartan therapy on heart failure with reduced ejection fraction (HFrEF). The researchers used tissue Doppler-derived mitral annular isovolumic contraction velocity (ICV) to assess systolic function and predict left ventricular (LV) reverse remodeling. The study found that ICV increased after sacubitril/valsartan therapy and added value to models predicting post-therapy LV ejection fraction recovery. The findings suggest that ICV changes can be used to assess treatment responses in HFrEF. [Extracted from the article]

A recent study conducted at Nanjing Medical University in China compared the effects of sacubitril/valsartan and olmesartan on the left atrial structure in hypertensive patients without heart failure with reduced ejection fraction (HFrEF). The study found that treatment with sacubitril/valsartan resulted in more significant improvements in left atrial and ventricular structure and function compared to olmesartan. The research was a single-center randomized controlled trial that included 145 patients who completed the 24-week assessment. These findings suggest that sacubitril/valsartan may be a more effective treatment option for hypertensive patients without HFrEF. [Extracted from the article]

A recent report from the KLE College of Pharmacy in Karnataka, India discusses the use of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), in the management of heart failure. The drug has been approved by the United States Food and Drug Administration for treating chronic heart failure with reduced ejection fraction (HFrEF). Clinical trials have shown that sacubitril/valsartan is effective in reducing hospitalizations and mortality rates associated with heart failure in various patient populations. The report explores the current landscape of cardiovascular medicine, the role of pharmacology, and the safety profile of this medication. [Extracted from the article]

A study conducted by Johns Hopkins University examined the effectiveness of sacubitril-valsartan, the first angiotensin receptor/neprilysin inhibitor on the market, for pediatric heart failure. The study found that there was no significant difference in the incidence of all-cause mortality or heart transplant within one year between patients who received sacubitril-valsartan and those who received an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. However, there was an increased incidence of hypotension in patients who received sacubitril-valsartan. The study suggests that further research is needed to evaluate the reduction in hospitalizations and optimal dosing to minimize hypotension. [Extracted from the article]

A study conducted at Yashoda Hospitals in Telangana, India, examined the effectiveness and tolerability of switching heart failure patients from the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan to perindopril. The study included 125 patients with heart failure with reduced ejection fraction (HFrEF), and data was collected on their New York Heart Association (NYHA) class, N-terminal pro hormone brain natriuretic peptide (NT-proBNP) levels, and left ventricular ejection fraction (LVEF) before and after the switch. The study found that the switch to perindopril was well tolerated and safe, with no significant changes in functional condition or NT-proBNP levels. There was a modest improvement in LVEF. The researchers noted that switching to perindopril is a less expensive option in India. [Extracted from the article]

Researchers at Pharos University Alexandria in Egypt have conducted a sustainability research study on the concurrent quantification of valsartan and sacubitril, two drugs used in cardiovascular therapy. The study aimed to develop analytical methods for the simultaneous analysis of these drugs, using highly sensitive and selective spectrofluorimetric techniques. The proposed methods were found to be sustainable and environmentally friendly, with excellent performance and affordability. The research highlights the growing interest in sustainable analytical chemistry for global environmental pollution control. [Extracted from the article]

A clinical trial has been launched to determine if heart failure patients with higher body mass index (BMI) can tolerate higher doses of the medication Entresto and experience better outcomes compared to patients with lower BMI. The study will enroll heart failure patients with reduced ejection fraction (HFrEF) and will evaluate the tolerability and efficacy of Entresto uptitration across different BMI categories. The primary outcomes of the study include the maximum tolerable dose of Entresto and the incidence of adverse drug reactions, while secondary outcomes include changes in heart failure symptoms, functional capacity, hospitalization rates, and mortality. The trial is currently recruiting participants and is expected to be completed by December 2024. [Extracted from the article]

A recent study conducted at Newcastle University in the United Kingdom examined the effects of sacubitril/valsartan treatment on patients with non-obstructive hypertrophic cardiomyopathy (HCM). The study, which involved 115 patients, found that after 16 weeks of treatment, there was no significant change in exercise capacity, cardiac structure, or function in the group receiving sacubitril/valsartan compared to the control group. The researchers concluded that while the treatment was well tolerated, it did not have a significant impact on HCM. This study provides valuable insights into the potential limitations of sacubitril/valsartan therapy for HCM. [Extracted from the article]

A report from the University of Alexandria in Egypt discusses the use of chemometrics approaches in sustainable analytical chemistry procedure development. The research focuses on the analysis of LCZ696, an antihypertensive supramolecular complex, and its in-process and degradation impurity. The study found that using chemometric data handling techniques reduced the time and solvent consumption required for analysis. The researchers also plan to compare their methodology with other chromatographic methods in terms of environmental impact. [Extracted from the article]

A recent study conducted by researchers at the Graduate School of Medicine in Osaka, Japan, explored the effects of LCZ696, an angiotensin receptor-neprilysin inhibitor, on endothelial dysfunction in diabetic mice. The study found that LCZ696 improved endothelium-dependent vascular relaxation in diabetic mice, potentially through increased bioavailability of atrial natriuretic peptide (ANP). The researchers concluded that LCZ696 may have a vascular protective effect in diabetic models and could be more effective than valsartan. This research has been peer-reviewed and published in the Journal of Atherosclerosis and Thrombosis. [Extracted from the article]

A study conducted at Hebei University in Baoding, China, investigated the efficacy of combining sacubitril/valsartan sodium with metoprolol tartrate for chronic heart failure (CHF) and its relation to vascular endothelial function and neuroendocrine function. The study involved 96 patients with CHF who were divided into a control group and an observation group. After three months of treatment, the observation group showed significantly higher improvement in various measures, including left ventricular function, exercise tolerance, and self-care ability, compared to the control group. The study concluded that the combination therapy effectively enhances cardiac function and improves vascular endothelial and neuroendocrine function in CHF patients. [Extracted from the article]

A study conducted by researchers at Minia University in Egypt explored the protective effects of sacubitril/valsartan (SAC/VAL) on intestinal ischemia-reperfusion (IIR) injury. IIR is a serious condition that requires immediate intervention, and the small intestine is particularly vulnerable to this type of injury. The study found that SAC/VAL administration significantly reduced markers of inflammation, oxidative stress, and apoptosis, while increasing antioxidant parameters. Additionally, SAC/VAL improved the histological structure of the intestine. These findings suggest that SAC/VAL may prevent IIR-induced damage through its modulation of various pathways. [Extracted from the article]

A meta-analysis conducted by researchers at Beijing University of Chinese Medicine compared the efficacy of sacubitril/valsartan with olmesartan for the control of hypertension. The analysis included seven randomized controlled trials and 3,677 patients. The results showed that sacubitril/valsartan treatment was associated with significantly decreased systolic blood pressure, diastolic blood pressure, and pulse pressure, as well as improved systolic blood pressure control. However, it had no influence on diastolic blood pressure control or adverse events. The researchers concluded that sacubitril/valsartan is better than olmesartan for reducing blood pressure in patients with hypertension. [Extracted from the article]

A recent study conducted by researchers at Comenius University in Bratislava, Slovakia, explored the potential protective effects of angiotensin receptor-neprilysin inhibitors (ARNIs) in hypertensive heart disease. The study used a rat model of hypertension induced by L-NAME and compared the effects of ARNI treatment with an angiotensin-converting enzyme inhibitor, captopril. The results showed that ARNI treatment reduced blood pressure, alleviated left ventricular hypertrophy and fibrosis, and prevented the development of both systolic and diastolic dysfunction. These findings suggest that ARNIs may offer protection against structural remodeling and functional disorders in hypertensive heart disease. [Extracted from the article]

A recent study conducted by researchers at Ain Shams University has found that sacubitril/valsartan therapy can be effective in improving electrocardiogram (ECG) and echocardiographic parameters in heart failure patients with reduced ejection fraction (HFrEF). The study enrolled 100 patients with non-ischemic dilated cardiomyopathy and assessed the effect of sacubitril/valsartan therapy on ECG indices and their relationship to echocardiographic parameters. The results showed that sacubitril/valsartan therapy not only improved echocardiogram parameters and New York Heart Association (NYHA) class, but also improved QRS width and corrected QTc interval on ECG. These findings suggest that sacubitril/valsartan therapy may contribute to reverse electrical left ventricular remodeling and can be used as an auxiliary prediction for tracking therapy outcomes in HFrEF patients. [Extracted from the article]

A recent systematic review and meta-analysis conducted in Chongqing, People's Republic of China, compared the renoprotective effects of sacubitril/valsartan (Sac/Val) with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in patients with heart failure. The study found that Sac/Val significantly reduced the risk of renal function decline compared to ACEI/ARB, particularly in patients with heart failure. However, further research is needed to fully understand the potential of Sac/Val as a nephroprotective agent. This research provides valuable insights into the comparative effectiveness of different medications for heart failure patients. [Extracted from the article]

A study conducted at Dazhou Central Hospital in Sichuan, China compared the efficacy of combining left bundle branch pacing (LBBP) with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF). The study retrospectively reviewed the records of 138 CHF patients and found that after six months of treatment, patients in the sacubitril/valsartan group had lower myocardial injury markers, higher cardiopulmonary function indicators, and lower scores on the Minnesota Living with Heart Failure Questionnaire compared to the enalapril group. The study concluded that the combination of LBBP with sacubitril/valsartan had a better therapeutic effect in improving cardiopulmonary function, reducing myocardial injury, and improving quality of life in CHF patients. [Extracted from the article]

A study conducted at MLN Medical College in India evaluated the effectiveness and safety of Sacubitril/Valsartan in the management of heart failure (HF) in the Indian population. The study involved newly diagnosed adult patients with HF who were treated with Sacubitril/Valsartan in a tertiary care hospital. After three months of treatment, there was a significant improvement in left ventricular ejection fraction (LVEF), a decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and improvement in clinical symptoms such as breathlessness, edema, and palpitations. The study suggests that Sacubitril/Valsartan is associated with symptomatic improvement in Indian patients with HF. [Extracted from the article]

Researchers from Comenius University conducted a study to investigate the effects of sacubitril/valsartan and valsartan on left ventricular fibrotic remodeling and dysfunction in two experimental models of pre-hypertension. The study found that both sacubitril/valsartan and valsartan reduced elevated systolic blood pressure, left ventricular hypertrophy and fibrosis, and improved left ventricular systolic and diastolic function in both models. The researchers concluded that the protective effects of sacubitril/valsartan and valsartan were related to the blockade of angiotensin II and the protective angiotensin 1-7, with additional benefits in the lactacystin-induced pre-hypertension model due to reduced aldosterone levels. This research provides valuable insights into potential treatments for pre-hypertension. [Extracted from the article]

Researchers from Sapir College in Ashkelon, Israel, have conducted a study comparing the cost-effectiveness of two medications, dapagliflozin and sacubitril-valsartan, in the treatment of heart failure with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF). Both medications have shown reductions in the combined risk of cardiovascular death and HF hospitalizations in patients with HFmrEF or HFpEF. The study found that dapagliflozin provides better monetary value than sacubitril-valsartan in preventing the composite outcome of total HF hospitalizations and cardiovascular disease among these patients. The research suggests that dapagliflozin may be a more cost-effective treatment option for HFmrEF or HFpEF. [Extracted from the article]

A new report from Rice Lake, Wisconsin presents fresh data on heart failure. The report states that sacubitril/valsartan improves heart failure outcomes in patients with reduced ejection fraction. However, randomized controlled trials in patients with mildly reduced ejection fraction and preserved ejection fraction have shown inconsistent results. A meta-analysis was conducted to evaluate the efficacy and safety of sacubitril/valsartan compared to valsartan in these patient populations. The study found that sacubitril/valsartan was superior to valsartan in improving certain heart failure outcomes, such as the Kansas City Cardiomyopathy Questionnaire Clinical Score and the New York Heart Association class. However, there was no additional benefit in terms of cardiovascular death and all-cause mortality. Sacubitril/valsartan was associated with a higher risk of hypotension but did not increase the risk of hyperkalemia or worsening renal function. Overall, sacubitril/valsartan can result in improvements in heart failure outcomes in patients with mildly reduced and preserved ejection fractions. [Extracted from the article]

A recent study conducted by researchers at the University of Florida compared the effectiveness of sacubitril/valsartan (SAC/VAL) and angiotensin receptor blockers (ARBs) in patients with heart failure with preserved ejection fraction (HFpEF). The study used real-world data from patients aged 18 and older who initiated SAC/VAL or ARB therapy. After analyzing the data, the researchers found that there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between patients who received SAC/VAL and those who received ARB therapy. This study provides valuable insights into the comparative effectiveness of these two treatments for HFpEF patients. [Extracted from the article]

A study conducted at Kuban State Medical University examined the long-term effects of sacubitril/valsartan and candesartan on women with chronic heart failure and reduced left ventricular ejection fraction (LVEF) after chemotherapy for breast cancer. The study found that sacubitril/valsartan was more effective than candesartan in improving left ventricular function, reducing ventricular arrhythmias, and lowering the risk of cardiovascular death. However, there was no significant difference between the two groups in terms of mortality due to breast cancer progression or recurrence. The researchers concluded that sacubitril/valsartan can be considered a safe and effective option for protecting the cardiovascular system during potentially cardiotoxic polychemotherapy for breast cancer in patients with chronic heart failure. [Extracted from the article]

A systematic review conducted by researchers from Mayo Clinic in Rochester, Minnesota, evaluated the cardiovascular benefits and safety of sacubitril-valsartan in patients with end-stage kidney disease (ESKD) who are on dialysis. The analysis of 12 studies involving 799 eligible patients with ESKD revealed that sacubitril-valsartan improved left ventricular ejection fraction (LVEF) in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with moderately reduced ejection fraction (HFmrEF), but not in patients with heart failure with preserved ejection fraction (HFpEF). The safety analysis indicated no increased risk of hyperkalemia, hypotension, or angioedema with sacubitril-valsartan compared to standard care. However, the safety analysis is limited due to the observational nature of the studies. [Extracted from the article]

A recent study conducted at the University Medical Center Hamburg-Eppendorf in Germany explored the effects of Sacubitril/Valsartan (Sac/Val) on hypertrophy, a condition characterized by an increase in the size of heart muscle cells. The researchers found that Sac/Val improved cardiac function and reduced hypertrophy and fibrosis in a mouse model of hypertrophy. Additionally, the study suggested that the beneficial effects of Sac/Val were primarily derived from the Sac component rather than the Val component. This research provides valuable insights into the mechanisms underlying the therapeutic effects of Sac/Val in the treatment of heart failure. [Extracted from the article]

A meta-analysis conducted by researchers at Nanchang University in Jiangxi, China, examined the effectiveness and safety of sacubitril-valsartan (SV) as a treatment for heart failure. The analysis included ten randomized controlled trials with a total of 18,164 heart patients. The results showed that SV was effective in reducing the number of heart patients and had minimal risk and side effects compared to control drugs. The researchers concluded that SV is an effective treatment for heart failure, reducing hospitalization and cardiovascular mortality. [Extracted from the article]

A study conducted in Jinan, People's Republic of China, investigated the efficacy and tolerability of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF) and low systolic blood pressure (SBP). The study found that within an optimized heart failure follow-up management system, sacubitril/valsartan was well-tolerated and led to left ventricular reverse remodeling in patients with HFrEF who had asymptomatic hypotension. The study observed similar reductions in N-terminal pro-B-type natriuretic peptide levels and improvements in left ventricular ejection fraction in patients with SBP < 100 mmHg and SBP = 100 mmHg. No significant differences were observed in the occurrence of adverse events between the two groups. [Extracted from the article]

A study conducted by Kyushu University in Fukuoka, Japan, examined the long-term treatment of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction (HFrEF). The study enrolled 150 patients who received sacubitril/valsartan in addition to optimal background heart failure therapy. The researchers found that long-term sacubitril/valsartan at doses up to 200 mg, b.i.d., was safe and well-tolerated in Japanese patients with chronic HFrEF. The study concluded that sacubitril/valsartan has a positive risk-benefit profile for these patients. [Extracted from the article]

A new study conducted in Almaty, Kazakhstan, explores the use of sacubitril/valsartan therapy in patients with heart failure after coronary artery bypass graft (CABG) surgery. The study aimed to evaluate the safety and efficacy of early initiation of sacubitril/valsartan in patients with reduced ejection fraction after CABG. The results showed that the early initiation of sacubitril/valsartan was safe and effective, with low rates of adverse events and discontinuation. The study also found significant improvements in quality of life and exercise capacity in both groups. This research provides valuable insights into the potential benefits of sacubitril/valsartan therapy for patients with heart failure after CABG. [Extracted from the article]

Researchers from the University of Indonesia have conducted a study on the effectiveness of sacubitril/valsartan in preventing heart failure in patients who have undergone percutaneous coronary intervention (PCI) following ST-elevation myocardial infarction (STEMI). The study found that sacubitril/valsartan was more effective than angiotensin-converting enzyme (ACE) inhibitors in reducing the risk of heart failure at 6 months post-PCI. The research suggests that sacubitril/valsartan may be a viable treatment option for reducing the risk of heart failure in STEMI patients. Further information on the study can be found in the Journal of Internal Medicine Indonesia. [Extracted from the article]

A recent study conducted at Tangshan GongRen Hospital in Hebei, China, explored the effects of LCZ696 on heart function in rats with diabetic heart disease. LCZ696 is a medication that combines a neprilysin inhibitor and an angiotensin receptor blocker and has been reported to protect against diabetic cardiomyopathy (DCM). The study found that treatment with LCZ696 improved cardiac function, reduced myocardial apoptosis and fibrosis, and activated the Akt/FoxO1 signaling pathway. These findings suggest that LCZ696 could be a potential therapeutic agent for DCM. [Extracted from the article]

A report from Huazhong University of Science and Technology in Wuhan, China discusses the effect of sacubitril/valsartan (Sac/Val) compared to valsartan in patients with nonvalvular atrial fibrillation (AF) without systolic heart failure (SHF). The study found that Sac/Val treatment did not increase the percentage of sinus rhythm and did not significantly improve NT-proBNP levels or cardiac function compared to valsartan. Subgroup analysis also showed no significant differences in echocardiographic measures. The research concludes that Sac/Val is not superior to valsartan for short-term treatment of AF without SHF. [Extracted from the article]

A recent study conducted by researchers at New York Medical College has found that sacubitril-valsartan (LCZ696) may be an effective treatment for hypertension. Sacubitril-valsartan acts as an inhibitor of both neprilysin and the renin-angiotensin-aldosterone system, providing a multi-faceted approach to managing hypertension. The study suggests that sacubitril-valsartan may be particularly beneficial for Asian populations with salt-sensitive hypertension and individuals over the age of 65 with systolic hypertension. Additionally, patients with treatment-resistant hypertension, especially those with heart failure, may also experience improved blood pressure with sacubitril-valsartan. Further research is needed to explore the potential role of sacubitril-valsartan in managing noncardiac diseases. [Extracted from the article]

A pilot study conducted at Shanghai Jiao Tong University in China examined the use of sacubitril/valsartan, an angiotensin receptor neprilysin antagonist (ARNI), in pediatric patients with heart failure (HF) due to cardiomyopathy or congenital heart disease. The study included 45 patients with a median age of 7.86 years, and the primary endpoint of left ventricular ejection fraction (LVEF) up to 45% was reached by 53.3% of patients. The study found that sacubitril/valsartan may be effective in children with HF, but its safety and outcomes may vary depending on the cause and anatomy of HF. [Extracted from the article]

A recent study conducted by researchers from Columbia University in New York City examined the effects of sacubitril-valsartan, a medication used to treat heart failure with reduced ejection fraction. The study involved 40 patients who were already receiving guideline-directed medical therapy for heart failure. The researchers found that after one year of treatment with sacubitril-valsartan, there was a significant decrease in left ventricular volume and an increase in left ventricular ejection fraction. Additionally, right ventricular volume decreased and right ventricular global longitudinal strain improved. These findings suggest that sacubitril-valsartan can induce significant remodeling of both the left and right ventricles in patients with heart failure. The study was supported by Novartis and has been peer-reviewed. [Extracted from the article]

A study conducted by researchers at King Saud Bin Abdulaziz University for Health Sciences in Saudi Arabia aimed to compare the demographics and outcomes of patients in Saudi Arabia who received sacubitril/valsartan (Sac/Val) with those enrolled in the PARADIGM-HF trial. The study included 400 patients with heart failure with reduced ejection fraction (HFrEF) who were initiated on Sac/Val. The findings revealed notable disparities in the baseline characteristics of patients with HFrEF compared to those in the PARADIGM-HF trial, providing valuable real-world insights into the prescription patterns and outcomes of Sac/Val in Saudi Arabia. [Extracted from the article]

A study conducted by researchers from Herlev Gentofte University Hospital in Copenhagen, Denmark, examined the effects of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor) in high-risk myocardial infarction (MI) patients with left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. The study aimed to determine whether the use of mineralocorticoid receptor antagonists (MRA) modified the safety and clinical outcomes of sacubitril/valsartan. The results showed that the use of MRA did not significantly alter the safety or clinical endpoints related to the initiation of sacubitril/valsartan compared to ramipril in post-MI patients with LVSD and/or congestion. [Extracted from the article]

A recent study conducted at Brigham and Women's Hospital in Boston, Massachusetts examined the duration of heart failure (HF) with preserved ejection fraction (HFpEF) and the outcomes of sacubitril/valsartan therapy. The study found that longer HF duration was associated with higher comorbidity burdens and worse health status. However, the treatment effects of sacubitril/valsartan were consistent regardless of the baseline HF duration, suggesting that even patients with longstanding HFpEF and mild symptoms can benefit from treatment optimization. The study was published in the Journal of Cardiac Failure. [Extracted from the article]

A recent study conducted at Tohoku Medical and Pharmaceutical University in Sendai, Japan, has found that the administration of sacubitril/valsartan, a novel therapy for chronic heart failure, can lead to a significant increase in urinary C-peptide levels in patients with type 2 diabetes mellitus (T2DM) and hypertension. The study observed a 70-year-old man with T2DM and hypertension who experienced a dramatic increase in urinary C-peptide levels after taking sacubitril/valsartan, which then decreased after discontinuation of the drug. This finding suggests that the insulin secretory capacity of T2DM patients receiving sacubitril/valsartan may be overestimated when measuring urinary C-peptide levels. The research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A recent study has found that the common drug Entresto, used to treat heart failure, can interfere with a blood test for Alzheimer's disease. The blood test, called the plasma Ab ratio, is used to detect the presence of brain amyloidosis, a key pathology of Alzheimer's disease. The study showed that patients taking Entresto had a marked increase in plasma Ab40 and Ab42, leading to a reduction in the plasma Ab ratio and potentially causing false positive results for Alzheimer's disease. The findings suggest that caution should be exercised when interpreting the results of the plasma Ab test in patients taking Entresto, and further research is needed to re-evaluate previous studies on the test. [Extracted from the article]

A study conducted at the Chongqing Hospital of Traditional Chinese Medicine in China aimed to assess the impact of sacubitril/valsartan therapy on the quality of life of patients with heart failure and reduced/preserved ejection fraction. The study analyzed six clinical trials involving 16,854 patients with heart failure. The results showed that treatment with sacubitril/valsartan significantly improved the quality of life of patients compared to other treatments, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score. Additionally, the sacubitril/valsartan group had a lower mortality rate compared to the control group. However, there was no significant difference in the occurrence of serious adverse events between the two groups. This study suggests that sacubitril/valsartan may be an effective treatment option for improving the quality of life in patients with heart failure. [Extracted from the article]

This document provides information about a clinical trial, NCT06149806, that is currently recruiting participants in France. The trial aims to study the effectiveness and tolerability of Sacubitril/Valsartan in treating chronic heart failure in adults with complex congenital heart disease. Specifically, the trial will focus on patients with systemic right ventricle (SRV) and single ventricle (SV), who are at higher risk for heart failure. The study will also collect data on the safety and effectiveness of type 2 sodium-glucose co-transport inhibitors. The trial is observational, prospective, and multicenter, and it follows the latest heart failure treatment guidelines. The estimated completion date for the trial is December 2025, and the contact person for the study is Claire Massardier, MD. [Extracted from the article]

A recent study conducted at Peking University International Hospital investigated the effects of sacubitril-valsartan (SV), an angiotensin receptor-neprilysin inhibitor, on patients undergoing maintenance dialysis. The study included 102 end-stage kidney disease patients on dialysis, with 51 receiving SV treatment and 51 serving as the control group. The results showed that SV treatment led to a significant decrease in B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels, indicating a potential cardio-protective role for SV in dialysis patients. However, the study also noted a slightly higher rate of hyperkalemia in the SV group, suggesting the need for monitoring serum potassium levels during treatment. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, aimed to develop a method for monitoring the medication Entresto in pediatric patients with heart failure. The researchers successfully developed and validated a liquid chromatography tandem mass spectrometry method for quantifying the levels of valsartan, sacubitril, and sacubitrilat in human plasma. The method was tested on 39 children and demonstrated good accuracy, precision, and linearity. This study is believed to be the first to simultaneously measure the plasma concentrations of these substances in children and may aid in the clinical management of pediatric heart failure. [Extracted from the article]

A recent study conducted by researchers at the University of Naples Federico II in Italy aimed to understand medication adherence patterns among patients with heart failure. The study used longitudinal trajectory modeling to analyze prescription data and identify distinct adherence trajectories. The researchers found four distinct adherence groups: high adherence, partial drop-off, moderate adherence, and low adherence. Factors such as polypharmacy and hospitalizations were associated with lower adherence. The study suggests that tailored patient education, support, and ongoing monitoring can improve adherence and potentially enhance health outcomes. [Extracted from the article]